Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003
Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003
复制标题
DOI：
10.1111/j.1365-3156.2004.01281.x
复制
发表时间：
2004-08-01
影响因子：
3.3
通讯作者：
Leo, YS
中科院分区：
文献类型：
--
作者：
Leong, HN;Ang, B;Leo, YS
目的利巴韦林是一种广谱核苷类似物，可有效治疗多种病毒感染。在最近爆发的严重急性呼吸综合征(SARS)疫情中，利巴韦林被各国用于对抗这种新型冠状病毒。我们对利巴韦林在新加坡治疗SARS的疗效进行了回顾分析。97名患者(42.4%)接受利巴韦林治疗，平均病程为6.4天。将利巴韦林治疗开始时的临床和实验室参数与未接受治疗的患者的第5、6或7天的参数进行比较。两组比较采用Fisher‘s精确检验和学生t检验。多因素分析采用COX回归模型，以死亡为影响因素。结果治疗组有更多的年轻女性出现肌痛症状(P<；0.001)。对照组粗死亡率为12.9%，治疗组粗死亡率为10.3%(P=0.679)。在校正了年龄、男性、乳酸脱氢酶水平和类固醇使用后，危险比为1.0 3(95%CI：0.44~2.41，P=0.939)。
OBJECTIVE Ribavirin is a broad spectrum nucleoside analogue efficacious in the treatment of several viral infections. In the recent severe acute respiratory syndrome (SARS) outbreak, ribavirin was used in various countries against this novel coronavirus. We conducted a retrospective analysis to assess the efficacy of ribavirin in the treatment of SARS in Singapore.METHODS A total of 229 cases were analysed. Ninety-seven (42.4%) patients received ribavirin at a mean of 6.4 days of illness. Clinical and laboratory parameters taken at the start of ribavirin treatment were compared with day 5, 6 or 7 parameters of those patients not on treatment. The two groups were compared using Fisher's exact test and Student's t-test. Multivariate analysis was performed using Cox regression model with death as the outcome of interest.RESULTS The treatment group had younger women with more symptoms of myalgia (P < 0.001). The crude death rate was 12.9% in the control and 10.3% (P = 0.679) in the treatment group. After correction for age, male sex, lactate dehydrogenase levels and steroid use, the hazard ratio was 1.03 (95% CI: 0.44-2.41, P = 0.939).CONCLUSION In this retrospective, uncontrolled cohort analysis, use of ribavirin did not appear to confer any benefit for patients with SARS.